• Citer

Coronary heart disease risk factors and LDL cholesterol-lowering efficacy of fibrates and simvastatin

par Muls, Erik;Autier, Philippe;Malbecq, William ;Vansant, Greet
Référence Clinical drug investigation, 14, 2, page (98-108)
Publication Publié, 1997

Article révisé par les pairs

• Détails
• Contenu

Résumé :

The objective of this study was to assess the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of fibric acid derivatives (fibrates) and simvastatin as a function of coronary heart disease (CHD) risk status, stratified according to National Cholesterol Education Program guidelines. Two independent databases were analysed retrospectively. The first data set originated from a consecutive sample of 6340 patients with primary hypercholesterolaemia who completed the diet plus fibrate treatment phase of the Belgian General Practitioners Trial, an open-label, prospective study conducted in a primary care setting. The second data set was derived from 782 participants in five randomised, double-blind studies that each compared a specific fibrate with simvastatin. The main outcome measures were percentage of subjects reaching LDL-C treatment goal, and mean percentage reduction in LDL-C across 5 (first data set) or 3 (second data set) CHD risk strata. In the Belgian General Practitioners Trial, LDL-C lowering efficacy of fibrates was inversely related to CHD risk status as 15.0% of patients with prior CHD reached the LDL-C goal < 4.13 mmol/L (< 160 mg/dl) vs 30.2% of those without CHD and no other risk factor (p < 0.0001 after adjustment for baseline LDL-C acid triglycerides). Adjusted mean percentage reductions in LDL-C were 15.1 and 18.2, in these strata, respectively (p < 0.05). Younger age, male gender, high blood pressure, low high-density lipoprotein cholesterol, and history of prior CHD were significant (p < 0.05) negative determinants of both outcome measures in multivariate analyses that adjusted for other risk factors. In the pooled analysis of five randomised trials, the percentage of fibrate-treated patients with prior atherosclerotic disease reaching LDL-C goal < 4.20 mmol/L (< 162 mg/dl) was significantly lower when compared with those without CHD and no risk factor other than LDL-C (adjusted odds ratio = 0.46; p = 0.009), while simvastatin efficacy was similar across CHD risk strata. In conclusion, our results, derived from two independent databases, suggest that the LDL-C lowering efficacy of fibrates, but not of simvastatin, is inversely related to CHD risk status. This exploratory analysis must be confirmed by future prospective studies.